Pfizer said that the Phase IIb/III ALLEGRO trial on ritlecitinib was found to be effective against the autoimmune disease, which is characterized by an immune attack on hair follicles.
Shares of Zymergen plummeted by 68% Tuesday from its April IPO price of $31 per share to just $11.7 per share after news that the company will not likely see revenue anytime soon.
The company announced that it is withdrawing its peripheral T-cell lymphoma drug Istodax from the market after recent trials showed that it does not achieve its primary efficacy endpoint.
The FDA has already given its go-ahead to use lumasiran to treat PH1 and lower the urinary oxalate levels in pediatric and adult patients under the brand name OXLUMO.
Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a “pay-for-delay” scheme that cost the former millions of dollars.
The research will focus on accelerating the capacities of BLU-222, an investigational therapy that Blueprint designed to target cyclin-dependent kinase 2 (CDK2).
A breakthrough study has found that altering the genetic makeup of malaria-carrying mosquito species could be the key to stopping the spread of the malaria virus and finally eradicating the disease.
Regeneron and AstraZeneca are looking to research, develop, and eventually commercialize a new drug that targets GPR75, the gene associated with obesity.
The companies will co-finance a clinical study to test the combination of SHP2 inhibitor BBP-398 and OPDIVO in treating patients with advanced solid tumors KRAS mutations.
